Stock Earnings

Question 1

What are SymBio Pharmaceuticals Ltd's key financial statements?

Accepted Answer

According to the latest financial statement (Form-10K), SymBio Pharmaceuticals Ltd has a total asset of $4,968, Net loss of $-3,833

Question 2

What are the key financial ratios for SYMQY?

Accepted Answer

SymBio Pharmaceuticals Ltd's Current ratio is 6.45, has a Net margin is -156.32, sales per share of $54.37.

Question 3

How is SymBio Pharmaceuticals Ltd's revenue broken down by segment or geography?

Accepted Answer

SymBio Pharmaceuticals Ltd largest revenue segment is Pharmaceuticals, at a revenue of 2,452,912,000 in the most earnings release.For geography, Japan is the primary market for SymBio Pharmaceuticals Ltd, at a revenue of 2,452,912,000.

Question 4

Is SymBio Pharmaceuticals Ltd profitable?

Accepted Answer

no, according to the latest financial statements, SymBio Pharmaceuticals Ltd has a net loss of $-3,833

Question 5

Does SymBio Pharmaceuticals Ltd have any liabilities?

Accepted Answer

yes, SymBio Pharmaceuticals Ltd has liability of 770

Question 6

How many outstanding shares for SymBio Pharmaceuticals Ltd?

Accepted Answer

SymBio Pharmaceuticals Ltd has a total outstanding shares of 45.83

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	1,525	2,452	5,589	10,008	8,256	2,987
Revenue Growth (YoY)	-50%	-56%	-44%	21%	176%	5%
Cost of Revenue	401	579	1,178	2,408	2,456	2,120
Gross Profit	1,124	1,873	4,411	7,599	5,800	866
Selling, General & Admin	5,549	2,370	2,584	3,009	2,979	3,066
Research & Development	--	3,379	2,638	2,554	1,736	2,266
Operating Expenses	5,549	5,750	5,222	5,636	4,784	5,373
Other Non Operating Income (Expenses)	-112	-16	-20	-100	2	-70
Pretax Income	-4,539	-3,806	-1,195	2,106	1,001	-4,086
Income Tax Expense	14	26	767	927	-1,030	3
Net Income	-4,554	-3,833	-1,962	1,179	2,032	-4,090
Net Income Growth	13%	95%	-266%	-42%	-150%	-7%
Shares Outstanding (Diluted)	49.61	45.09	39.9	39.6	38.84	32.95
Shares Change (YoY)	8%	13%	1%	2%	18%	42%
EPS (Diluted)	-91.78	-85	-49.19	29.77	52.32	-124.13
EPS Growth	5%	73%	-265%	-43%	-142%	-34%
Free Cash Flow	--	-3,463	-427	1,580	76	-4,271
Free Cash Flow Per Share	--	-76.78	-10.7	39.89	1.95	-129.61
Gross Margin	73.7%	76.38%	78.92%	75.92%	70.25%	28.99%
Operating Margin	-290.16%	-158.07%	-14.51%	19.61%	12.3%	-150.85%
Profit Margin	-298.62%	-156.32%	-35.1%	11.78%	24.61%	-136.92%
Free Cash Flow Margin	--	-141.23%	-7.64%	15.78%	0.92%	-142.98%
EBITDA	--	--	-715	2,035	1,084	-4,466
EBITDA Margin	--	--	-12.79%	20.33%	13.12%	-149.51%
D&A For EBITDA	--	--	96	72	68	40
EBIT	-4,425	-3,876	-811	1,963	1,016	-4,506
EBIT Margin	-290.16%	-158.07%	-14.51%	19.61%	12.3%	-150.85%
Effective Tax Rate	-0.3%	-0.68%	-64.18%	44.01%	-102.89%	-0.07%

SymBio Pharmaceuticals Ltd (SYMQY) Price

SYMQY Stock Price Chart

SYMQY Income

Follow-Up Questions